Physician profile
Afreen Sheikh
NPI 1841941630
$1,814.99
in general payments reported to CMS, 2019-2025
17 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $323 · 2024: $1,030 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $411.24 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $390.35 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Inspire Medical Systems, INC. | $336.33 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $138.99 | 2023-2024 | Yupelri |
| Grifols USA, LLC | $83.57 | 2023-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $83.56 | 2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $57.02 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.51 | 2023-2025 | Jascayd, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $50.26 | 2024-2025 | |
| Insmed, INC. | $39.46 | 2025 | Brinsupri, Arikayce |
| Novo Nordisk INC | $38.64 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.56 | 2025 | Caplyta |
| Harmony Biosciences LLC | $26.87 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.54 | 2024 | Uptravi, Opsumit |
| Verona Pharma, INC. | $20.86 | 2025 | Ohtuvayre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $15.23 | 2025 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2024 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afreen Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.